Drugs / PER-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05822245 | May 2023 → Apr 2025 | open-angle glaucoma | Perfuse Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06003751 | Aug 2023 → Apr 2025 | diabetic retinopathy | Perfuse Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PER-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06003751 ↗ |
| Route | Intravitreal | “PER-001 Low Dose Intravitreal Implant” NCT05822245 ↗ |